2015
Local delivery of paclitaxel in the treatment of peripheral arterial disease
Ng VG, Mena C, Pietras C, Lansky AJ. Local delivery of paclitaxel in the treatment of peripheral arterial disease. European Journal Of Clinical Investigation 2015, 45: 333-345. PMID: 25615282, DOI: 10.1111/eci.12407.Peer-Reviewed Original ResearchConceptsPeripheral artery diseaseEndovascular revascularizationArtery diseaseLocal deliveryClinical studiesLocal drug deliveryPeripheral arterial diseasePeripheral vascular diseasePrimary patency rateSystemic adverse effectsUse of paclitaxelLong-term efficacyDrug-Eluting BalloonDrug-eluting stentsTerms of efficacyBrief exposure periodArterial diseaseBalloon angioplastyPatency ratesVascular diseaseBalloon catheterCoated balloonMEDLINE searchStent failureActive drug
2004
Impact of intravenous Beta-Blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction
Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Brodie B, Turco M, Rutherford BD, Aymong E, Lansky AJ, Stone GW. Impact of intravenous Beta-Blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. Journal Of The American College Of Cardiology 2004, 43: 1780-1787. PMID: 15145099, DOI: 10.1016/j.jacc.2003.10.068.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCIBeta-blocker useMyocardial recoveryMyocardial infarctionLate Angioplasty Complications (CADILLAC) trialOral beta-blocker medicationOral beta-blocker useLeft ventricular ejection fractionIntravenous beta blockadeMechanical reperfusion therapyAbsence of contraindicationsBeta-blocker therapyBeta-blocker medicationBeta-blocker administrationPercutaneous coronary interventionVentricular ejection fractionBeta blockadeControlled AbciximabPrimary angioplastyReperfusion therapyComplications TrialCoronary interventionSurvival benefit
1999
Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion
Teirstein P, Mann J, Cundey P, Schechter E, Jacobs W, Grines C, Stagaman D, Lansky A, Hultquist M, Kusnick B, Heuser R, Kleinert H, Popma J. Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion. The American Journal Of Cardiology 1999, 83: 1623-1628. PMID: 10392865, DOI: 10.1016/s0002-9149(99)00163-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsCerebral HemorrhageChronic DiseaseCoronary AngiographyCoronary DiseaseDose-Response Relationship, DrugFemaleGraft Occlusion, VascularHeparinHumansInfusions, IntravenousMaleMiddle AgedPlasminogen ActivatorsRecombinant ProteinsSaphenous VeinUrokinase-Type Plasminogen ActivatorConceptsSaphenous vein graftsR-UKStudy drugVein graftsMyocardial infarctionNon-Q-wave myocardial infarctionPrimary study end pointSaphenous vein graft occlusionHigh-dose armStudy end pointLife-threatening bleedingVein graft occlusionHigh-dose groupDuration of infusionRecombinant urokinaseAcceptable success rateIntracerebral bleedPercutaneous revascularizationFinal angiogramGraft occlusionRecanalization rateAngiographic analysisHuman kidney cellsAllergic reactionsLow dose